Blog

CRI congratulates SURGE Therapeutics on their completion of a $32 million Series B financing – Cancer Research Institute

Photo from businesswire.com

Jul 22, 2023, 19:34

CRI congratulates SURGE Therapeutics on their completion of a $32 million Series B financing – Cancer Research Institute

CRI congratulates SURGE Therapeutics, led by former CRI CLIP Award Grantee Michael Goldberg, Ph.D, on their completion of a $32 million Series B financing! This funding will be used to further develop the SURGE intraoperative immunotherapy approach, expand the team, and advance multiple clinical trials for its injectable biodegradable hydrogel, which may be administered during any surgical oncology procedure. SURGE Therapeutics recently dosed the first two patients in a Phase 1/2a trial for its lead intraoperative immunotherapy candidate, STM-416, in patients with recurrent bladder cancer, a major unmet medical need, to improve post-resection outcomes.

Read the full press release: Click here

Source: Cancer Research Institute/Linkedin

biodegradable hydrogel bladder cancer cancer Cancer Research Institute clinical trials immunotherapy Michael Goldberg OncoDaily Oncology SURGE Therapeutics

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

Special Coverage